Lead Optimization of a Novel Series of Imidazo[1,2-<i>a</i>]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent
-
- Jungjun Kim
- Qurient Incorporated, 16 Daewnagpangyo-ro, 712 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Korea
-
- Kiyean Nam
- Qurient Incorporated, 16 Daewnagpangyo-ro, 712 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Korea
書誌事項
- 公開日
- 2014-06-17
- DOI
-
- 10.1021/jm5003606
- 公開者
- American Chemical Society (ACS)
この論文をさがす
収録刊行物
-
- Journal of Medicinal Chemistry
-
Journal of Medicinal Chemistry 57 (12), 5293-5305, 2014-06-17
American Chemical Society (ACS)
